Tassone DF - Search Results

1

Antibody response to the COVID-19 ChAdOx1nCov-19 and BNT162b vaccines after temporary suspension of DMARD therapy in immune-mediated inflammatory disease: an extension study (RESCUE 2).

Tran AP, Tassone DF, Ding NS, Nossent J. Tran AP, et al. Among authors: tassone df. RMD Open. 2023 Mar;9(1):e002871. doi: 10.1136/rmdopen-2022-002871. RMD Open. 2023. PMID: 36863751 Free PMC article.

2

Immunosuppression as a risk factor for COVID-19: a meta-analysis.

Tassone D, Thompson A, Connell W, Lee T, Ungaro R, An P, Ding Y, Ding NS. Tassone D, et al. Intern Med J. 2021 Feb;51(2):199-205. doi: 10.1111/imj.15142. Intern Med J. 2021. PMID: 33631862 Free PMC article.

3

Systematic Review: The Impact and Importance of Body Composition in Inflammatory Bowel Disease.

Ding NS, Tassone D, Al Bakir I, Wu K, Thompson AJ, Connell WR, Malietzis G, Lung P, Singh S, Choi CR, Gabe S, Jenkins JT, Hart A. Ding NS, et al. J Crohns Colitis. 2022 Sep 8;16(9):1475-1492. doi: 10.1093/ecco-jcc/jjac041. J Crohns Colitis. 2022. PMID: 35325076 Free PMC article.

4

Antibody response to the COVID-19 ChAdOx1nCov-19 and BNT162b vaccines after temporary suspension of DMARD therapy in immune-mediated inflammatory disease (RESCUE).

Tran AP, Tassone D, Nossent J, Ding NS. Tran AP, et al. RMD Open. 2022 May;8(1):e002301. doi: 10.1136/rmdopen-2022-002301. RMD Open. 2022. PMID: 35577478 Free PMC article. Clinical Trial.

5

Letter: tofacitinib in the real world - do clinical trial data stand up?

Gilmore R, Tassone D, Ding NS. Gilmore R, et al. Aliment Pharmacol Ther. 2023 Mar;57(6):745-746. doi: 10.1111/apt.17402. Aliment Pharmacol Ther. 2023. PMID: 36821748 No abstract available.

6

Letter: diagnostic delay in inflammatory bowel disease.

Tassone D, Gilmore R, Lee T, Ding NS. Tassone D, et al. Aliment Pharmacol Ther. 2023 May;57(10):1203-1204. doi: 10.1111/apt.17483. Aliment Pharmacol Ther. 2023. PMID: 37094304 No abstract available.

7

Risk factors for malignancy and serious infection in patients with inflammatory bowel disease: a retrospective analysis.

Tassone D, Basnayake C, Wright E, Lust M, Kamm MA, Niewiadomski O, Schulberg J, Flanagan E, Samyue T, Fry S, Malcolm R, Stanley A, Thompson AJ, Connell WR, Ding NS. Tassone D, et al. Intern Med J. 2024 Mar;54(3):446-454. doi: 10.1111/imj.16141. Epub 2023 Jun 21. Intern Med J. 2024. PMID: 37255273

8

Letter: Combatting sarcopenia to improve clinical outcomes in inflammatory bowel disease.

Tassone D, Hartley I, Ding NS. Tassone D, et al. Aliment Pharmacol Ther. 2023 Aug;58(3):376-377. doi: 10.1111/apt.17596. Aliment Pharmacol Ther. 2023. PMID: 37452587 No abstract available.

9

Letter: Muscle thickness measurement using ultrasound-A step closer to the use of body composition analysis in the management of inflammatory bowel disease.

Tassone D, Hartley I, Ding NS. Tassone D, et al. Aliment Pharmacol Ther. 2023 Oct;58(7):729-730. doi: 10.1111/apt.17671. Aliment Pharmacol Ther. 2023. PMID: 37702030 No abstract available.

10

Editorial: The prevalence and outcomes of perianal Crohn's disease across treatment eras.

Tassone D, Hartley I, Ding NS. Tassone D, et al. Aliment Pharmacol Ther. 2024 Mar;59(5):713-714. doi: 10.1111/apt.17861. Aliment Pharmacol Ther. 2024. PMID: 38349699 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

13 results

Search Page

Filters